Download MendeleyDiscovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.
Rajapaksa, N.S., Gobbi, A., Drobnick, J., Do, S., Kolesnikov, A., Liang, J., Chen, Y., Sujatha-Bhaskar, S., Huang, Z., Brightbill, H., Francis, R., Yu, C., Choo, E.F., DeMent, K., Ran, Y., An, L., Emson, C., Maher, J., Wai, J., McKenzie, B.S., Lupardus, P.J., Zarrin, A.A., Kiefer, J.R., Bryan, M.C.(2020) ACS Med Chem Lett 11: 327-333
- PubMed: 32184965
- DOI: https://doi.org/10.1021/acsmedchemlett.9b00380
- Primary Citation of Related Structures:
6UYA - PubMed Abstract:
IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.
Organizational Affiliation:
Genentech, Inc., One DNA Way, South San Francisco, California 94080, United States.
